203 related articles for article (PubMed ID: 36109341)
1. Process design of a fully integrated continuous biopharmaceutical process using economic and ecological impact assessment.
Ding C; Ardeshna H; Gillespie C; Ierapetritou M
Biotechnol Bioeng; 2022 Dec; 119(12):3567-3583. PubMed ID: 36109341
[TBL] [Abstract][Full Text] [Related]
2. Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study.
Xu J; Xu X; Huang C; Angelo J; Oliveira CL; Xu M; Xu X; Temel D; Ding J; Ghose S; Borys MC; Li ZJ
MAbs; 2020 Jan; 12(1):1770669. PubMed ID: 32425110
[TBL] [Abstract][Full Text] [Related]
3. Process intensification in fed-batch production bioreactors using non-perfusion seed cultures.
Yongky A; Xu J; Tian J; Oliveira C; Zhao J; McFarland K; Borys MC; Li ZJ
MAbs; 2019; 11(8):1502-1514. PubMed ID: 31379298
[TBL] [Abstract][Full Text] [Related]
4. An automated high inoculation density fed-batch bioreactor, enabled through N-1 perfusion, accommodates clonal diversity and doubles titers.
Olin M; Wolnick N; Crittenden H; Quach A; Russell B; Hendrick S; Armstrong J; Webster T; Hadley B; Dickson M; Hodgkins J; Busa K; Connolly R; Downey B
Biotechnol Prog; 2024; 40(2):e3410. PubMed ID: 38013663
[TBL] [Abstract][Full Text] [Related]
5. Economic assessment of continuous processing for manufacturing of biotherapeutics.
Gupta P; Kateja N; Mishra S; Kaur H; Rathore AS
Biotechnol Prog; 2021 Mar; 37(2):e3108. PubMed ID: 33305493
[TBL] [Abstract][Full Text] [Related]
6. Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production.
Dizon-Maspat J; Bourret J; D'Agostini A; Li F
Biotechnol Bioeng; 2012 Apr; 109(4):962-70. PubMed ID: 22094920
[TBL] [Abstract][Full Text] [Related]
7. A Different Perspective: How Much Innovation Is Really Needed for Monoclonal Antibody Production Using Mammalian Cell Technology?
Kelley B; Kiss R; Laird M
Adv Biochem Eng Biotechnol; 2018; 165():443-462. PubMed ID: 29721583
[TBL] [Abstract][Full Text] [Related]
8. Design and operation of a continuous integrated monoclonal antibody production process.
Steinebach F; Ulmer N; Wolf M; Decker L; Schneider V; Wälchli R; Karst D; Souquet J; Morbidelli M
Biotechnol Prog; 2017 Sep; 33(5):1303-1313. PubMed ID: 28691347
[TBL] [Abstract][Full Text] [Related]
9. Pilot-scale demonstration of an end-to-end integrated and continuous biomanufacturing process.
Coolbaugh MJ; Varner CT; Vetter TA; Davenport EK; Bouchard B; Fiadeiro M; Tugcu N; Walther J; Patil R; Brower K
Biotechnol Bioeng; 2021 Sep; 118(9):3287-3301. PubMed ID: 33410159
[TBL] [Abstract][Full Text] [Related]
10. Process performance and product quality in an integrated continuous antibody production process.
Karst DJ; Steinebach F; Soos M; Morbidelli M
Biotechnol Bioeng; 2017 Feb; 114(2):298-307. PubMed ID: 27497430
[TBL] [Abstract][Full Text] [Related]
11. Integrated continuous biomanufacturing platform with ATF perfusion and one column chromatography operation for optimum resin utilization and productivity.
Kamga MH; Cattaneo M; Yoon S
Prep Biochem Biotechnol; 2018 May; 48(5):383-390. PubMed ID: 29509101
[TBL] [Abstract][Full Text] [Related]
12. Process-wide control and automation of an integrated continuous manufacturing platform for antibodies.
Feidl F; Vogg S; Wolf M; Podobnik M; Ruggeri C; Ulmer N; Wälchli R; Souquet J; Broly H; Butté A; Morbidelli M
Biotechnol Bioeng; 2020 May; 117(5):1367-1380. PubMed ID: 32022243
[TBL] [Abstract][Full Text] [Related]
13. Model-based design and control of a small-scale integrated continuous end-to-end mAb platform.
Gomis-Fons J; Schwarz H; Zhang L; Andersson N; Nilsson B; Castan A; Solbrand A; Stevenson J; Chotteau V
Biotechnol Prog; 2020 Jul; 36(4):e2995. PubMed ID: 32233078
[TBL] [Abstract][Full Text] [Related]
14. A new, integrated, continuous purification process template for monoclonal antibodies: Process modeling and cost of goods studies.
Xenopoulos A
J Biotechnol; 2015 Nov; 213():42-53. PubMed ID: 25959171
[TBL] [Abstract][Full Text] [Related]
15. Integrated continuous production of recombinant therapeutic proteins.
Warikoo V; Godawat R; Brower K; Jain S; Cummings D; Simons E; Johnson T; Walther J; Yu M; Wright B; McLarty J; Karey KP; Hwang C; Zhou W; Riske F; Konstantinov K
Biotechnol Bioeng; 2012 Dec; 109(12):3018-29. PubMed ID: 22729761
[TBL] [Abstract][Full Text] [Related]
16. Transfer of a three step mAb chromatography process from batch to continuous: Optimizing productivity to minimize consumable requirements.
Gjoka X; Gantier R; Schofield M
J Biotechnol; 2017 Jan; 242():11-18. PubMed ID: 27939321
[TBL] [Abstract][Full Text] [Related]
17. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality.
Yang WC; Lu J; Kwiatkowski C; Yuan H; Kshirsagar R; Ryll T; Huang YM
Biotechnol Prog; 2014; 30(3):616-25. PubMed ID: 24574326
[TBL] [Abstract][Full Text] [Related]
18. Enablers of continuous processing of biotherapeutic products.
Rathore AS; Zydney AL; Anupa A; Nikita S; Gangwar N
Trends Biotechnol; 2022 Jul; 40(7):804-815. PubMed ID: 35034769
[TBL] [Abstract][Full Text] [Related]
19. Improving an intensified and integrated continuous bioprocess platform for biologics manufacturing.
Zhou H; Fang M; Zheng X; Zhou W
Biotechnol Bioeng; 2021 Sep; 118(9):3618-3623. PubMed ID: 33788278
[TBL] [Abstract][Full Text] [Related]
20. Enhancing protein A productivity and resin utilization within integrated or intensified processes.
Brinkmann A; Elouafiq S
Biotechnol Bioeng; 2021 Sep; 118(9):3359-3366. PubMed ID: 33638385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
